本周主题2025 年有数十个AI 衍生的管线进入人体临床试验，但回顾过往管线来看，与任何其他新技术的发展一样，AI 制药的发展之路也是曲折的。AI 制药极大加速了临床早期的进程同时亦能取得超出传统经验水平的1 期成功率（80%~90% vs 40%~65%），而在2 期及后续的进展中表现尚未看出差异优势（成功率在~40%）。从发展态势来看，AI 在临床端出现了快速的创新进展：从分子设计、试验规划到...
Source Link本周主题2025 年有数十个AI 衍生的管线进入人体临床试验，但回顾过往管线来看，与任何其他新技术的发展一样，AI 制药的发展之路也是曲折的。AI 制药极大加速了临床早期的进程同时亦能取得超出传统经验水平的1 期成功率（80%~90% vs 40%~65%），而在2 期及后续的进展中表现尚未看出差异优势（成功率在~40%）。从发展态势来看，AI 在临床端出现了快速的创新进展：从分子设计、试验规划到...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.